trial

Safety and Tolerability Study of Single-dose Administration of Brexpiprazole in Adult Subjects With Schizophrenia

NCTId NCT02968121
as of 2026-07-01
Add to landscapeMonitor thisAsk about this
at a glance
Phase 1 · Terminated
Enrollment 22 (actual)
Sponsored by Otsuka Pharmaceutical Development & Commercialization, Inc.
Primary completion 2017-12-14
Synthesized from structured facts only — each point cited above.

Design & status

Phase
Phase 1
Status
Terminated
Enrollment
22 (actual)
Study type
Interventional
Allocation
Randomized
Model
Parallel
Masking
None
Start
2017-01
Primary completion
2017-12-14
Eligibility
ALL · 18 Years · 64 Years

Interventions & indications

Drugs
Brexpiprazole (Rexulti)

Sponsors

Otsuka Pharmaceutical Development & Commercialization, Inc.Lead Sponsor
H. Lundbeck A/SCollaborator

Sites

2 total
Garden Grove, United StatesSan Diego, United States

Facts & assertions

4 sourced
Enrollment
22
Phase
PHASE1
Primary Completion Date
2017-12-14
Status
TERMINATED
relationships
The graph out of here
drug
Brexpiprazole (Rexulti)
drug
lead_sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
company
collaborator
H. Lundbeck A/S
company
indication
Schizophrenia
indication
Schizophrenia
indication